Alpha Tau Medical (DRTS) CFO Raphi Levy Sells $167K of Stock

Raphi Levy, the Chief Financial Officer of DRTS, sold 17,500 shares of the company on June 23, 2026. This planned transaction was executed at an average price of $9.55 per share, totaling $167,049.75 in value. Shares of DRTS traded near $9.89 on Thursday.

Other Institutional Activity in DRTS

Institutional investors have been active in DRTS recently. Hightower Advisors, LLC grew its holdings by 188,440 shares, ending with 874,994 shares worth about $6.19 million. Aquamarine Financial (Cayman) Ltd opened a new position with 721,501 shares valued at approximately $5.10 million. Apella Capital, LLC held steady with 382,284 shares, valued at $3.07 million. UBS Group AG significantly increased its stake by 265,988 shares, resulting in a total of 286,688 shares valued at about $2.03 million. Meanwhile, Northcoast Asset Management LLC reduced its position by 10,720 shares, holding 147,138 shares worth $1.04 million.

Insider Buying and Selling at Alpha Tau Medical Ltd.

Raphi Levy has been actively trading DRTS shares. Apart from the recent planned sale on June 23, he sold 32,500 shares on June 3, 2026, at an average price of $10.84. Earlier in the year, Levy executed several planned sales, including selling 10,000 shares on February 25 at $7.4 per share and 15,000 shares on January 13 at $7.09 per share.

Analysts Set New Price Targets

On June 4, 2026, Barclays maintained a 'buy' rating on DRTS with a price target of $17. Piper Sandler, on May 19, held its 'hold' rating with a target of $8. Ladenburg Thalmann and HC Wainwright & Co. both maintained 'buy' ratings with targets of $14 and $15, respectively, in May.

Bottom Line

Raphi Levy's recent planned sale of DRTS shares is a routine insider transaction. DRTS's stock activity and institutional interest suggest ongoing engagement from investors. As always, these transactions are reported after the fact and may not indicate future performance.